GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » PB Ratio

Cormedix (Cormedix) PB Ratio : 4.57 (As of May. 05, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cormedix PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Cormedix's share price is $5.84. Cormedix's Book Value per Share for the quarter that ended in Dec. 2023 was $1.28. Hence, Cormedix's PB Ratio of today is 4.57.

The historical rank and industry rank for Cormedix's PB Ratio or its related term are showing as below:

CRMD' s PB Ratio Range Over the Past 10 Years
Min: 1.3   Med: 3.67   Max: 51.92
Current: 4.57

During the past 13 years, Cormedix's highest PB Ratio was 51.92. The lowest was 1.30. And the median was 3.67.

CRMD's PB Ratio is ranked worse than
73.55% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs CRMD: 4.57

During the past 12 months, Cormedix's average Book Value Per Share Growth Rate was -0.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -1.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 32.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cormedix was 93.70% per year. The lowest was -63.70% per year. And the median was 11.50% per year.

Back to Basics: PB Ratio


Cormedix PB Ratio Historical Data

The historical data trend for Cormedix's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix PB Ratio Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.90 5.64 2.76 3.28 2.94

Cormedix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.28 3.42 3.70 2.44 2.94

Competitive Comparison of Cormedix's PB Ratio

For the Biotechnology subindustry, Cormedix's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cormedix's PB Ratio falls into.



Cormedix PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Cormedix's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=5.84/1.277
=4.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Cormedix  (NAS:CRMD) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Cormedix PB Ratio Related Terms

Thank you for viewing the detailed overview of Cormedix's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix (Cormedix) Business Description

Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.
Executives
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry officer: Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco director, officer: Chief Executive Officer 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan director C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa director MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart director 360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione director ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David officer: EVP, Chief Financial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson officer: EVP, Head of Clinical Ops. 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel officer: EVP, Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan director 44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz director SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan director 700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L. officer: Exec VP of Tech Operations C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch director, officer: Chief Executive Officer 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921